No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis

MLA

Peter Hübener, et al. “No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.” Clinical Gastroenterology and Hepatology, vol. 14, Dec. 2016, pp. 1806–12. EBSCOhost, https://doi.org/10.1016/j.cgh.2016.07.032.

APA

Peter Hübener, M. Bubenheim, K. K. Jørgensen, Christina Weiler-Normann, Ansgar W. Lohse, N Pannicke, Tobias J. Weismüller, Christoph Schramm, Roman Zenouzi, Kornelius Schulze, Johannes Hartl, Marcial Sebode, Sina Hübener, Hanno Ehlken, Michael P. Manns, Henrike Lenzen, Kirsten Muri Boberg, Moritz Peiseler, & Tom H. Karlsen. (2016). No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 14, 1806–1812. https://doi.org/10.1016/j.cgh.2016.07.032

Chicago

Peter Hübener, M. Bubenheim, K. K. Jørgensen, Christina Weiler-Normann, Ansgar W. Lohse, N Pannicke, Tobias J. Weismüller, et al. 2016. “No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis.” Clinical Gastroenterology and Hepatology 14 (December): 1806–12. doi:10.1016/j.cgh.2016.07.032.